In order to test whether the functional findings that ING5 inhibits lung cancer aggressiveness could be reflected in clinical samples, we evaluated the expression of ING5 by immunohistochemistry on tissue microarrays containing 150 lung tumors and corresponding non-cancerous lung tissue (Supplemental Table 1) and examined the correlation of ING5 expression with clinicopathological parameters in lung cancer patients. The gene discussed is ING5; the disease is lung carcinoma.